Stockreport

LUXTURNA Continues to Lead in Retinal Gene Therapy with Increased Market Penetration | DelveInsight [Yahoo! Finance]

Ocugen, Inc.  (OCGN) 
PDF With its FDA approval for specific mutations in the RPE65 gene, it offers hope to patients who previously had limited options. The growing awareness and adoption of gene [Read more]